Kaufmann E Hattori H Miyatake-Ondozabal H Gademann K 2015 The first enantioselective total synthesis of fidaxomicin, also known as tiacumicin B or lipiarmycin A3, is reported. This novel glycosylated macrolide antibiotic is used in the clinic for the treatment of Clostridium difficile infections. Key features of the synthesis involve a rapid and high-yielding access to the noviose, rhamnose, and orsellinic acid precursors; the first example of a β-selective noviosylation; an effective Suzuki coupling of highly functionalized substrates; and a ring-closing metathesis reaction of a noviosylated dienoate precursor. Careful selection of protecting groups allowed for a complete deprotection yielding totally synthetic fidaxomicin. https://sonar.ch/global/documents/109531 eng info:eu-repo/semantics/altIdentifier/doi/10.1021/acs.orglett.5b01602 info:eu-repo/semantics/altIdentifier/pmid/26125969 Organic letters. - 2015 Aminoglycosides Anti-Bacterial Agents Clostridium Infections Clostridium difficile Fidaxomicin Glycosylation Macrolides Molecular Structure Vancomycin Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin. http://purl.org/coar/resource_type/c_6501